The Cordis Biologics Delivery Systems Group is a leader in the emerging field of biologics delivery, developing breakthrough technology in targeted delivery across multiple disease states and clinical specialties. Biologics Delivery Systems Group delivery technology is advancing the standard of care by enabling physicians to identify and visualize optimal delivery sites, and to precisely target single and multiple treatment sites.
Biologics Delivery Systems works in partnership with a variety of other leading companies and organizations focused on coronary artery disease to conduct studies, clinical trials and other important initiatives to advance learning and continue driving development of complete solutions for better healthcare outcomes.
For more information, call 1-877-237-6868 or email email@example.com.
Biosense Webster is recognized worldwide as a leader in the science behind the diagnosis and treatment of cardiac arrhythmias. The first useful deflectable tip catheter was pioneered by Will Webster more than three decades ago. Ever since, Biosense Webster has defined the state of design and craftsmanship in diagnostic and therapeutic cardiac catheters. In fact, we offer more electrophysiology catheter designs than anyone else in the industry. But beyond numbers, our continuous pursuit of practical innovation has led to a steady flow of breakthrough designs.
At the same time, Biosense Webster has delivered mapping and navigation innovations that have advanced the science and practice of electrophysiology. Ongoing research and development at Biosense Webster has given EPs access to 3-D, real-time, color-coded views into the heart’s electrical activity, allowing diagnosis and treatment with increasing precision. And collaboration with leaders in related industries is pushing the clinical boundaries still further, thanks to such new technologies as remote magnetic navigation and intracardiac echocardiography (ICE).
Guided by the needs of electrophysiologists and cardiologists, Biosense Webster has pioneered innovative technological advancements for more than 30 years. Some might call this quite a heritage. At Biosense Webster, we say it’s just the beginning.
For more information about Biosense Webster and its products, please visit www.biosensewebster.com
Conor Medsystems, LLC, founded in 1999, is a developer of innovative controlled vascular drug delivery technology, called Reservoir (RES) Technology™. Conor has initially focused on the development of drug-eluting stents to treat coronary artery disease. Most drug-eluting stents currently available are multipurpose bare-metal stents that have been surface coated with polymer. Stents developed with RES Technology™ will not need to be surface coated. Rather each stent has hundreds of small holes – reservoirs – in the stent struts, loaded with a bioresorbable drug-polymer matrix. This matrix is designed to deliver drug in a variety of release kinetics. Over time, the drug-polymer matrix is resorbed with no polymer left behind. A variety of therapeutic goals could potentially be achieved through unique combinations of controlled drug release from these reservoirs.
Conor’s efforts are currently focused on the development of drug-eluting stents for the treatment of restenosis. Conor is also investigating the potential applicability of its stent technology for myocardial rescue in setting of acute MI, treatment of reperfusion injury, and treatment of diabetic restenosis. To learn more about RES Technology™ please visit www.res-technology.com
In 2007, Conor Medsystems LLC became a member of the Johnson and Johnson family of companies, the world's most comprehensive and broadly based manufacturer of healthcare products. Conor Medsystems is an affiliate of Cordis Corporation. The Cordis franchise welcomes to its family of products the Reservoir (RES) Technology™ platform developed by Conor Medsystems.
Products using RES Technology™ are under development and are not approved or available for sale in any market.
In March 2013, Cordis Corporation acquired Flexible Stenting Solutions, Inc. (FSS), a leading developer of third-generation flexible peripheral stents and reconstrainable delivery systems. This acquisition marks another milestone in Cordis’ strategy to lead in the endovascular market. The addition of Flexible Stenting Solutions’ FLEXSTENT ® Self-Expanding Stent System provides Cordis with the opportunity to launch the next generation S.M.A.R.T.® Stent platform. The S.M.A.R.T.® Flex System shares a design heritage with the S.M.A.R.T.® Stent and was designed by one of the principal designers and developers of the S.M.A.R.T.® Stent at Cordis. The S.M.A.R.T.® Flex System is the next innovation in self-expanding stents. It is designed to optimize flexibility, fracture resistance and predictable placement while maintaining the radial strength of the S.M.A.R.T.® Stent. This acquisition also provides Cordis with the opportunity to address unmet needs in the treatment of peripheral artery disease and the potential to expand its portfolio of therapeutic applications into below-the-knee and venous interventions. An estimated 27 million people in Europe and North America alone suffer from PAD.
For more information or questions pertaining to FLEXSTENT ® clinical trials please contact 1-877-DEVICE-5 (338-4235).